MX363347B - Sal de omecamtiv mecarbilo y proceso para preparar la sal. - Google Patents

Sal de omecamtiv mecarbilo y proceso para preparar la sal.

Info

Publication number
MX363347B
MX363347B MX2015012414A MX2015012414A MX363347B MX 363347 B MX363347 B MX 363347B MX 2015012414 A MX2015012414 A MX 2015012414A MX 2015012414 A MX2015012414 A MX 2015012414A MX 363347 B MX363347 B MX 363347B
Authority
MX
Mexico
Prior art keywords
salt
omecamtiv mecarbil
preparing
omecamtiv
mecarbil
Prior art date
Application number
MX2015012414A
Other languages
English (en)
Other versions
MX2015012414A (es
Inventor
Bradley Paul Morgan
Alan Martin Allgeier
Sheng Cui
Henry Morrison
Karthik Nagapudi
Shawn Walker
Charles Bernard
Karl Bennett Hansen
Neil Fred Langille
Steven Mennen
Jacqueline Woo
Alex Muci
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX363347(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2015012414A publication Critical patent/MX2015012414A/es
Publication of MX363347B publication Critical patent/MX363347B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan formas de sal de dihidrocloruro de omecamtiv mecarbil, composiciones y formulaciones farmacéuticas de las mismas, y métodos para su preparación y uso. El omecamtiv mecarbil (AMG 423, CK-1827452), teniendo la estructura:(ver Fórmula).
MX2015012414A 2013-03-14 2014-03-14 Sal de omecamtiv mecarbilo y proceso para preparar la sal. MX363347B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785763P 2013-03-14 2013-03-14
PCT/US2014/027146 WO2014152270A1 (en) 2013-03-14 2014-03-14 Salt of omecamtiv mecarbil and process for preparing salt

Publications (2)

Publication Number Publication Date
MX2015012414A MX2015012414A (es) 2016-04-25
MX363347B true MX363347B (es) 2019-03-20

Family

ID=50549466

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015012414A MX363347B (es) 2013-03-14 2014-03-14 Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2015012429A MX2015012429A (es) 2013-03-14 2014-03-14 Compuestos heterociclicos y sus usos.
MX2021001231A MX2021001231A (es) 2013-03-14 2015-09-11 Compuestos heterociclicos y sus usos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2015012429A MX2015012429A (es) 2013-03-14 2014-03-14 Compuestos heterociclicos y sus usos.
MX2021001231A MX2021001231A (es) 2013-03-14 2015-09-11 Compuestos heterociclicos y sus usos.

Country Status (42)

Country Link
US (15) US9988354B2 (es)
EP (3) EP3821882A1 (es)
JP (5) JP6783138B2 (es)
KR (2) KR102474467B1 (es)
CN (3) CN105120844A (es)
AP (1) AP2015008789A0 (es)
AR (2) AR095542A1 (es)
AU (2) AU2014240049C1 (es)
BR (2) BR112015023417B1 (es)
CA (2) CA2902646C (es)
CL (1) CL2015002708A1 (es)
CR (1) CR20150549A (es)
CY (2) CY1122695T1 (es)
DK (2) DK2968173T3 (es)
EA (1) EA031185B1 (es)
ES (2) ES2750676T5 (es)
HK (1) HK1218080A1 (es)
HR (2) HRP20201967T1 (es)
HU (2) HUE046285T2 (es)
IL (2) IL240788B (es)
JO (1) JOP20140114B1 (es)
LT (2) LT2970123T (es)
MA (2) MA44637B1 (es)
ME (1) ME03566B (es)
MX (3) MX363347B (es)
MY (2) MY186048A (es)
NZ (1) NZ711225A (es)
PE (1) PE20151786A1 (es)
PH (2) PH12019500176B1 (es)
PL (2) PL2970123T3 (es)
PT (2) PT2970123T (es)
RS (2) RS59536B1 (es)
RU (1) RU2663663C2 (es)
SA (1) SA515361088B1 (es)
SG (2) SG10201706656RA (es)
SI (2) SI2968173T1 (es)
SM (2) SMT202000685T1 (es)
TN (1) TN2015000380A1 (es)
TW (1) TWI667026B (es)
UA (1) UA117011C2 (es)
UY (1) UY35449A (es)
WO (2) WO2014152236A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014495A (es) 2004-06-17 2007-03-01 Cytokinetics Inc Compuestos, composiciones y metodos.
KR102474467B1 (ko) 2013-03-14 2022-12-05 암젠 인크 복소환식 화합물 및 그들의 용도
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
WO2019006235A1 (en) 2017-06-30 2019-01-03 Amgen Inc. METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS
TWI769272B (zh) * 2017-06-30 2022-07-01 美商安進公司 奧美卡替莫卡必爾的合成
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
EP3594199B1 (en) * 2018-07-09 2020-07-01 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
JP2021534138A (ja) * 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
CN114025845A (zh) * 2019-03-12 2022-02-08 安进股份有限公司 心肌肌钙蛋白活化剂的多晶型物
AU2020234995A1 (en) * 2019-03-12 2021-10-21 Amgen Inc. Polymorphs and cocrystals of a cardiac troponin activator
US20220348543A1 (en) * 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041198A4 (en) * 2019-10-09 2023-08-16 Dr. Reddy's Laboratories Limited SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF
WO2021163172A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
JP7825954B2 (ja) * 2020-08-26 2026-03-09 アムジエン・インコーポレーテツド Ｍｃｌ－１阻害剤処方物
SI4243825T1 (sl) 2020-11-12 2026-01-30 Amgen Inc. Omekamtiv mekarbil za zdravljenje srčnega popuščanja pri izbranih skupinah bolnikov
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
US11702380B2 (en) 2021-03-10 2023-07-18 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788775B1 (fr) 1999-01-22 2001-04-13 Pf Medicament Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique
PT1242055E (pt) 1999-12-23 2008-07-02 Pfizer Prod Inc Forma de dosagem de fármaco baseada em hidrogel
GB0124455D0 (en) 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
MXPA04003022A (es) 2001-10-17 2004-07-05 Aventis Pharma Gmbh Metodo para reducir diabetes tipo 2 en pacientes de alto riesgo.
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
MXPA06014495A (es) * 2004-06-17 2007-03-01 Cytokinetics Inc Compuestos, composiciones y metodos.
WO2007054975A1 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
TW200738243A (en) 2005-11-15 2007-10-16 Glaxo Group Ltd Novel process and formulations
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
TW200808321A (en) * 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7989455B2 (en) * 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US7639112B2 (en) 2007-04-25 2009-12-29 Sony Corporation Fuse device with integrated switch
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
JP5591245B2 (ja) 2008-10-03 2014-09-17 ペリコー セラピューティクス， インコーポレイテッド 急性心不全の治療のための方法および組成物
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
CA2902424A1 (en) * 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
KR102474467B1 (ko) 2013-03-14 2022-12-05 암젠 인크 복소환식 화합물 및 그들의 용도
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
WO2019006235A1 (en) 2017-06-30 2019-01-03 Amgen Inc. METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS
TWI769272B (zh) 2017-06-30 2022-07-01 美商安進公司 奧美卡替莫卡必爾的合成
EP3594199B1 (en) 2018-07-09 2020-07-01 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041198A4 (en) 2019-10-09 2023-08-16 Dr. Reddy's Laboratories Limited SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021136477A1 (zh) 2020-01-03 2021-07-08 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
WO2021163172A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
SI4243825T1 (sl) 2020-11-12 2026-01-30 Amgen Inc. Omekamtiv mekarbil za zdravljenje srčnega popuščanja pri izbranih skupinah bolnikov
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
US11702380B2 (en) 2021-03-10 2023-07-18 Amgen Inc. Synthesis of omecamtiv mecarbil
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
PE20151786A1 (es) 2015-12-11
EP2968173A1 (en) 2016-01-20
JP2016513683A (ja) 2016-05-16
US20180312469A1 (en) 2018-11-01
US20240217933A1 (en) 2024-07-04
ES2837038T3 (es) 2021-06-29
CA3147180A1 (en) 2014-09-25
JOP20140114B1 (ar) 2021-08-17
PL2970123T3 (pl) 2020-03-31
US20230044617A1 (en) 2023-02-09
EP2970123B1 (en) 2019-08-14
IL241089B (en) 2019-10-31
CY1123633T1 (el) 2022-03-24
CY1122695T1 (el) 2021-03-12
EP2968173B1 (en) 2020-10-14
ES2750676T5 (en) 2026-03-12
AU2014239995A1 (en) 2015-09-10
UY35449A (es) 2014-09-30
JP2022023891A (ja) 2022-02-08
US20220153700A1 (en) 2022-05-19
JP2020125307A (ja) 2020-08-20
WO2014152270A1 (en) 2014-09-25
IL240788B (en) 2020-09-30
US20220298114A1 (en) 2022-09-22
SG11201507258PA (en) 2015-10-29
JP6783138B2 (ja) 2020-11-11
CN105209437A (zh) 2015-12-30
PT2970123T (pt) 2019-10-28
JP6966590B2 (ja) 2021-11-17
HRP20201967T1 (hr) 2021-03-05
BR112015022857B1 (pt) 2022-10-25
US12275704B2 (en) 2025-04-15
SMT202000685T1 (it) 2021-01-05
SG10201706656RA (en) 2017-09-28
US11884630B2 (en) 2024-01-30
MY204971A (en) 2024-09-25
PH12015501998B1 (en) 2016-01-11
TN2015000380A1 (en) 2017-01-03
EP2970123B2 (en) 2025-12-10
TW201524507A (zh) 2015-07-01
AU2014239995B2 (en) 2018-07-26
KR20150136063A (ko) 2015-12-04
EP3821882A1 (en) 2021-05-19
US11384053B2 (en) 2022-07-12
US20200331859A1 (en) 2020-10-22
NZ711225A (en) 2020-06-26
US12221417B2 (en) 2025-02-11
CN105120844A (zh) 2015-12-02
PT2968173T (pt) 2020-12-18
US20240317687A1 (en) 2024-09-26
BR112015023417B1 (pt) 2023-10-17
JP6689942B2 (ja) 2020-04-28
BR112015023417A2 (pt) 2017-07-18
CA2902646C (en) 2022-08-16
KR102474467B1 (ko) 2022-12-05
EA031185B1 (ru) 2018-11-30
EP2970123A1 (en) 2016-01-20
AP2015008789A0 (en) 2015-10-31
AR095542A1 (es) 2015-10-21
CA3147180C (en) 2024-04-23
US20200277261A1 (en) 2020-09-03
HUE052355T2 (hu) 2021-04-28
HK1218544A1 (en) 2017-02-24
MA38399B2 (fr) 2020-12-31
US20160016906A1 (en) 2016-01-21
SMT201900563T1 (it) 2019-11-13
US20140309235A1 (en) 2014-10-16
KR102374159B1 (ko) 2022-03-15
CR20150549A (es) 2016-01-04
MA38399A1 (fr) 2017-01-31
AU2014240049A1 (en) 2015-09-10
HK1219484A1 (zh) 2017-04-07
US20250376444A1 (en) 2025-12-11
WO2014152236A1 (en) 2014-09-25
MX2015012429A (es) 2016-04-07
CN108785265A (zh) 2018-11-13
PH12015501998A1 (en) 2016-01-11
CN108785265B (zh) 2024-10-08
SI2970123T1 (sl) 2019-12-31
US20180273479A1 (en) 2018-09-27
CA2902436A1 (en) 2014-09-25
RU2663663C2 (ru) 2018-08-08
HK1218512A1 (zh) 2017-02-24
MX2021001231A (es) 2021-04-12
AR129504A2 (es) 2024-09-04
JP2019059746A (ja) 2019-04-18
RU2015143643A (ru) 2017-04-18
US11958809B2 (en) 2024-04-16
US9951015B2 (en) 2018-04-24
SI2968173T1 (sl) 2021-04-30
MA44637A1 (fr) 2019-08-30
US20240101517A1 (en) 2024-03-28
MA44637B1 (fr) 2021-04-30
HUE046285T2 (hu) 2020-02-28
US20200399221A1 (en) 2020-12-24
ES2750676T3 (es) 2020-03-26
MX2015012414A (es) 2016-04-25
IL241089A0 (en) 2015-11-30
MY186048A (en) 2021-06-17
PH12019500176B1 (en) 2023-08-11
LT2970123T (lt) 2019-11-11
PH12019500176A1 (en) 2020-11-04
BR112015022857A2 (pt) 2017-07-18
DK2970123T3 (da) 2019-10-21
US11472773B2 (en) 2022-10-18
CN105209437B (zh) 2018-09-18
DK2970123T4 (da) 2026-01-26
US9988354B2 (en) 2018-06-05
HK1218080A1 (zh) 2017-02-03
TWI667026B (zh) 2019-08-01
US20200079736A1 (en) 2020-03-12
EA201591728A1 (ru) 2016-01-29
JP6498658B2 (ja) 2019-04-10
AU2014240049C1 (en) 2019-03-07
RS59536B1 (sr) 2019-12-31
PL2968173T3 (pl) 2021-03-08
ME03566B (me) 2020-07-20
HRP20191728T1 (hr) 2019-12-13
KR20220045014A (ko) 2022-04-12
NZ750950A (en) 2020-09-25
IL240788A0 (en) 2015-10-29
CL2015002708A1 (es) 2016-03-11
UA117011C2 (uk) 2018-06-11
US20250243163A1 (en) 2025-07-31
AU2014240049B2 (en) 2018-07-19
JP7174132B2 (ja) 2022-11-17
SA515361088B1 (ar) 2018-07-22
DK2968173T3 (da) 2020-12-21
CA2902646A1 (en) 2014-09-25
US10421726B2 (en) 2019-09-24
LT2968173T (lt) 2021-03-25
RS61215B1 (sr) 2021-01-29
JP2016519071A (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
AU2019268062A1 (en) Benzoquinolone inhibitors of VMAT2
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
PH12015502615B1 (en) Chemical compounds
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12014501991B1 (en) Phenicol antibacterials
TW201613864A (en) Novel compounds
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
UA115357C2 (uk) Похідні піридин-4-ілу
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
WO2014153495A9 (en) Novel stat3 inhibitors
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
WO2016033549A3 (en) (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
MX2016005222A (es) Tinturas acidas, proceso para su produccion y su uso.
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.